Suppr超能文献

肿瘤微环境刺激响应性纳米前药通过共递送 miRNA-21 调节剂克服吉西他滨化疗耐药性。

A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.

机构信息

The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu 322000, People's Republic of China.

Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, People's Republic of China.

出版信息

Biomed Mater. 2023 Apr 14;18(3). doi: 10.1088/1748-605X/acc8ac.

Abstract

Gemcitabine (Gem) has been recommended as a first-line clinical chemotherapeutics for pancreatic ductal adenocarcinoma (PDAC) treatment. Gem treatment could generate chemoresistance associated with abnormal expressions of multiple miRNAs. In the PDAC setting, miRNA-21 (miR-21) overexpression is an important contributing factor of inducing Gem chemoresistance. Inhibition of miR-21 can significantly increase Gem chemosensitivity, which requires an efficient delivery platform to conduct combinational Gem and miR-21 siRNA (miR-21i) therapy. Herein, we synthesized a tumor microenvironment (TME) stimuli-responsive poly(beta-amino ester)s (PBAE)-based polymer nano-prodrug (miR-21i@HA-Gem-SS-P12) that could co-deliver miR-21 siRNA and Gem. The disulfide linkages conjugating GEM onto PBAE can be triggered by elevated reduction stimulus in TME to release the cargo Gem. The hyaluronic acid (HA) fabrication further improved the drug accumulation at the tumor site. Benefiting from the multiple functional improvements and synergism between Gem and miR-21i, the miR-21i@HA-Gem-SS-P12 nano-prodrugs displayed superior tumor inhibition in PDACand. This study established an effective stimuli-responsive nano-prodrug strategy for cooperative treatment with small molecule agents and nucleotide modulators in PDAC.

摘要

吉西他滨(Gem)已被推荐为治疗胰腺导管腺癌(PDAC)的一线临床化疗药物。Gem 治疗可产生与多种 miRNA 异常表达相关的化疗耐药性。在 PDAC 环境中,miR-21(miR-21)过表达是诱导 Gem 化疗耐药的重要因素。抑制 miR-21 可显著提高 Gem 化疗敏感性,这需要一个有效的递送平台来进行联合 Gem 和 miR-21 siRNA(miR-21i)治疗。在这里,我们合成了一种肿瘤微环境(TME)刺激响应性聚(β-氨基酯)(PBAE)基聚合物纳米前药(miR-21i@HA-Gem-SS-P12),可共递送 miR-21 siRNA 和 Gem。连接 GEM 到 PBAE 上的二硫键可以被 TME 中升高的还原刺激触发,从而释放货物 Gem。透明质酸(HA)的制备进一步提高了药物在肿瘤部位的积累。得益于 Gem 和 miR-21i 之间的多种功能改进和协同作用,miR-21i@HA-Gem-SS-P12 纳米前药在 PDAC 中显示出优异的肿瘤抑制作用。本研究建立了一种有效的刺激响应性纳米前药策略,用于在 PDAC 中与小分子药物和核苷酸调节剂进行联合治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验